他汀类药物在心房颤动治疗中的多效性作用
摘要
目前,心房颤动(atrial fibrillation,AF)的发病机制仍未完全阐明。药物治疗仍是其重要治疗方法之一,传统的抗心律失常药物由于不良反应大、可致心律失常、停药后易复发等局限性受到限制。近年的研究发现,炎症、氧化应激、肾素一血管紧张素系统与AF有关,
出处
《浙江医学》
CAS
2012年第15期1313-1315,共3页
Zhejiang Medical Journal
参考文献24
-
1Bruins P, Velthuis H, Yazdanbakhsh A P, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia[J]. Circulation, 1997, 96:3542-3548.
-
2Watanabe E,Arakawa T,Uchiyama T,et aI.High-sensitivity C-re- active protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion[J]. Int J Cardiol.2006.108:346-353.
-
3Marcus G M, Whooley M A, Glidden D V, et al. Interleukin-6 and atrial fibrillation in patients with coronary artery disease:data from the Heart and Soul Study[J].Am Heart J,2008,155:303-309.
-
4Sata N, Hamada N, Horinouchi T, et al. C-reactive protein and atrail fibrillation.Is inflammation a consequence or a cause of a- trail fibrillation. Is inflammation[J].Jpn Heart J,2004,45:441-445.
-
5Watanabe T, Takeishi Y, Hirono O, et al. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation[J]. Heart AND Vessels, 2005,20:45-49.
-
6Robert B,Heather L,Irfan S,et al.Oxidative stress markers are associated with persistent atrial fibrillation[J]. Clin Chem, 2007, 53: 1652-1657.
-
7Kim Y M, Kattaeh H, nicotinamide adenine with the development Ramatunga C dinucleotide of atrial fibrill et al. Association of atria phosphate oxidase activity ation after cardiac surgery [J]. J Am Coil Cardiol,2008,51:68-74.
-
8Tsai C T, Lai L P,Kuo K T,et aI.Angiotensin II activates signal transducerand activators of ranscription 3 via Rac1 in atrial my- ocytesand fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling[J]. Circulation,2008,117:344- 355.
-
9Scherlag B J,Nakagawa H,Jackman W M,et al. Electrical stimulation to identify neural elements on the heart:their role in atrial fibrillation[J]. J Intery Card Electrophysiol,2005,13(suppl I):37-42.
-
10Kumagai K,Nakashima H,Saku K.The HMG-CoA reductase in- hibitor atorvastatin prevents atrial fibrillation by inhibiting in- flammation in acanine sterile pericarditis model[J].Carcliovasc Res,2004,62:105-111.
共引文献19
-
1丁雪燕,罗助荣.急性冠脉综合征血清脑钠肽水平及阿托伐他汀对其影响[J].东南国防医药,2009,11(1):37-39. 被引量:8
-
2孔德玲.他汀类药物非调脂应用现状[J].天津药学,2005,17(6):57-59. 被引量:1
-
3闫建萍,刘富全.普伐他汀治疗急性心肌梗死合并心房颤动[J].医药论坛杂志,2006,27(10):90-90. 被引量:3
-
4田士军.房颤的研究进展[J].河北医药,2006,28(12):1201-1202. 被引量:3
-
5黄桑,林涛,刘媛.急性心肌梗死合并心房颤动心脏复律后的辛伐他汀治疗[J].岭南心血管病杂志,2007,13(1):39-41. 被引量:2
-
6赵艳,周英.阿托伐他汀对冠心病患者心血管事件的影响[J].吉林医学,2007,28(4):460-461.
-
7赵霞.不同剂量辛伐他汀对急性心梗降脂疗效观察[J].中国医药指南(学术版),2007,5(10X):143-144. 被引量:1
-
8陈韬.阿托伐他汀治疗不稳定型心绞痛合并高脂血症52例分析[J].中国误诊学杂志,2008,8(34):8479-8480.
-
9高爱玲,乔亚京,韩雪梅,逯保军.胺碘酮治疗急性心肌梗死并发快速心房颤动的疗效观察[J].中国基层医药,2009,16(2):345-346. 被引量:6
-
10李自胜,李世学.阿托伐他汀治疗冠心病合并高脂血症疗效观察[J].中国误诊学杂志,2010,10(21):5084-5085. 被引量:3
-
1王顺先,赵红宁.阿托伐他汀钙对短暂性脑缺血发作患者颈动脉粥样硬化斑块和血脂的影响[J].深圳中西医结合杂志,2008,18(5):286-288. 被引量:3
-
2孙佳玉,刘广忠,李为民.PCI术前强化他汀治疗的新进展[J].心脏杂志,2016,28(3):348-351. 被引量:3
-
3李罡,郝英平.他汀类药物治疗慢性心力衰竭现状及进展[J].疑难病杂志,2009,8(7):443-446. 被引量:2
-
4李永红,葛志明,王其新,蔡尚郎,戴红艳,冯进波,安毅,张运.阿托伐他汀对高胆固醇血症患者血小板血管紧张素Ⅱ受体表达的影响[J].中华高血压杂志,2008,16(10):894-898. 被引量:4
-
5鲍晓.他汀类药物对心血管的保护作用[J].中山大学研究生学刊(自然科学与医学版),2004,25(4):1-6.
-
6王哲颖,孙剑锋,于平,王锐,郭永和.通心络对经皮冠脉介入治疗术后CRP、IL-6、可溶性CD40L水平的影响[J].中国老年学杂志,2013,33(8):1883-1884. 被引量:6
-
7梁春,吴宗贵.他汀类药物调脂治疗的昨天、今天和明天[J].上海医学,2005,28(4):270-273. 被引量:3
-
8李建军.他汀类药物非调脂作用及其机制(续9-1)[J].中国循环杂志,2011,26(2):155-155. 被引量:15
-
9杨磊磊,樊继援.FOXC2与胰岛素抵抗[J].国际内分泌代谢杂志,2007,27(B04):18-20. 被引量:1
-
10刘屹.他汀类药物在动脉粥样硬化中的应用[J].临床医药实践,2005,14(9):647-649.